2024
Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury
Aklilu A, Menez S, Baker M, Brown D, Dircksen K, Dunkley K, Gaviria S, Farrokh S, Faulkner S, Jones C, Kadhim B, Le D, Li F, Makhijani A, Martin M, Moledina D, Coronel-Moreno C, O’Connor K, Shelton K, Shvets K, Srialluri N, Tan J, Testani J, Corona-Villalobos C, Yamamoto Y, Parikh C, Wilson F, Sundararajan A, Wang A, Schretlen C, Singel D, Moss E, Aune F, Iantosca G, Zou G, Chernova I, Bitzel J, Hernandez J, Lindsley J, Dane K, Orias M, Mehta P, Zassman-Isner S, Wen Y, Freeman N. Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury. JAMA 2024, 332 PMID: 39454050, DOI: 10.1001/jama.2024.22718.Peer-Reviewed Original ResearchElectronic health recordsUsual careHealth recordsAction teamsClinicians of patientsHospitalized patientsFinal follow-upIntervention groupHealth systemStudy pharmacistsStudy physiciansMain OutcomesAssociated with adverse outcomesAcute kidney injuryRandomized clinical trialsPrimary outcomeIndividualized recommendationsNew HavenAdverse outcomesAKI detectionCareRhode IslandComposite outcomeFollow-upIntervention
2023
Longitudinal biomarkers and kidney disease progression after acute kidney injury
Wen Y, Xu L, Melchinger I, Thiessen-Philbrook H, Moledina D, Coca S, Hsu C, Go A, Liu K, Siew E, Ikizler T, Chinchilli V, Kaufman J, Kimmel P, Himmelfarb J, Cantley L, Parikh C, Consortium T. Longitudinal biomarkers and kidney disease progression after acute kidney injury. JCI Insight 2023, 8: e167731. PMID: 36951957, PMCID: PMC10243801, DOI: 10.1172/jci.insight.167731.Peer-Reviewed Original ResearchConceptsAcute kidney injuryIschemic reperfusion injuryKidney disease progressionKidney injuryTubular healthDisease progressionChronic kidney disease (CKD) incidenceCox proportional hazards regressionMurine acute kidney injuryKidney disease incidenceUrine KIM-1Proportional hazards regressionCKD progressionCKD transitionUrine uromodulinIncident CKDComposite outcomeKidney atrophyProspective cohortReperfusion injuryHazards regressionKIM-1Prognostic valueMCP-1Initial insult
2022
Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury
Wen Y, Thiessen-Philbrook H, Moledina DG, Kaufman JS, Reeves WB, Ghahramani N, Ikizler TA, Go AS, Liu KD, Siew ED, Himmelfarb J, Kimmel PL, Hsu CY, Parikh CR. Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury. Kidney International Reports 2022, 7: 1502-1513. PMID: 35812275, PMCID: PMC9263319, DOI: 10.1016/j.ekir.2022.03.026.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseKidney injury molecule-1Urine concentrationsCKD outcomesKidney injuryInverse associationUrine kidney injury molecule-1Progression of CKDIncident chronic kidney diseaseCox proportional hazards regressionAcute Kidney Injury studyInjury molecule-1Kidney disease progressionProportional hazards regressionChemoattractant protein-1CKD progressionComposite outcomeNeutrophil gelatinaseInterleukin-18Urine biomarkersHazards regressionKidney diseaseSubsequent sequelaeUrinary concentrations
2021
Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19
Menez S, Moledina DG, Thiessen-Philbrook H, Wilson FP, Obeid W, Simonov M, Yamamoto Y, Corona-Villalobos CP, Chang C, Garibaldi BT, Clarke W, Farhadian S, Dela Cruz C, Coca SG, Parikh CR, Investigators T, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19. American Journal Of Kidney Diseases 2021, 79: 257-267.e1. PMID: 34710516, PMCID: PMC8542781, DOI: 10.1053/j.ajkd.2021.09.008.Peer-Reviewed Original ResearchConceptsAdverse kidney outcomesNeutrophil gelatinase-associated lipocalinUrinary biomarkersBiomarker levelsKidney outcomesPrimary outcomeClinical AKIKidney injuryComposite outcomeCOVID-19KDIGO stage 3 AKIKidney injury molecule-1Cox proportional hazards regressionEpidermal growth factor levelsStage 3 AKIPrimary composite outcomeInjury molecule-1Kidney disease progressionGelatinase-associated lipocalinAdditional prognostic informationComposite outcome eventsProportional hazards regressionCOVID-19 patientsGrowth factor levelsCoronavirus disease 2019Urinary EGF and MCP-1 and risk of CKD after cardiac surgery
Menez S, Ju W, Menon R, Moledina DG, Thiessen Philbrook H, McArthur E, Jia Y, Obeid W, Mansour SG, Koyner JL, Shlipak MG, Coca SG, Garg AX, Bomback AS, Kellum JA, Kretzler M, Parikh CR, . Urinary EGF and MCP-1 and risk of CKD after cardiac surgery. JCI Insight 2021, 6: e147464. PMID: 33974569, PMCID: PMC8262289, DOI: 10.1172/jci.insight.147464.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedAged, 80 and overCardiac Surgical ProceduresChemokine CCL2Disease ProgressionEpidermal Growth FactorFemaleGene Expression ProfilingHumansIncidenceMalePostoperative ComplicationsProportional Hazards ModelsRenal Insufficiency, ChronicRNA, MessengerRNA-SeqSingle-Cell AnalysisConceptsAcute kidney injuryCardiac surgeryMCP-1CKD outcomesUrinary EGFLong-term kidney outcomesChronic kidney disease riskTRIBE-AKI (Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury) ConsortiumKidney disease riskMCP-1 levelsRisk of CKDAmerican Heart AssociationPostoperative urine samplesHealth Research InstituteLong-term careCKD incidenceKidney outcomesKidney injuryKidney Precision Medicine ProjectComposite outcomeTubular damageHeart AssociationCCL2 expressionGlomerular functionKidney Center
2019
Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery
Patel DM, Thiessen-Philbrook H, Brown JR, McArthur E, Moledina DG, Mansour SG, Shlipak MG, Koyner JL, Kavsak P, Whitlock RP, Everett AD, Malenka DJ, Garg AX, Coca SG, Parikh CR. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American Heart Journal 2019, 220: 253-263. PMID: 31911262, PMCID: PMC7008086, DOI: 10.1016/j.ahj.2019.11.014.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersBlood ProteinsCardiac Surgical ProceduresCardiovascular DiseasesCause of DeathCohort StudiesCoronary Artery BypassFemaleGalectin 3GalectinsHeart Valve Prosthesis ImplantationHumansInterleukin-1 Receptor-Like 1 ProteinMalePostoperative ComplicationsProspective StudiesVentricular RemodelingConceptsGal-3 levelsCardiovascular eventsCardiac surgerySignificant post-operative morbidityGalectin-3Gal-3 valuesPlasma soluble ST2Composite primary outcomePrimary composite outcomePost-operative morbidityCongestive heart failurePost-operative changesPotential clinical utilityRandom-effects modelPlasma sST2Soluble suppressionComposite outcomeHazard ratioProspective cohortTumorigenicity 2Heart failurePrimary outcomeMyocardial remodelingClinical covariatesClinical utility